Literature DB >> 11589684

Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population.

A Ruiz1, G Antiñolo, R M Fernández, C Eng, I Marcos, S Borrego.   

Abstract

OBJECTIVE: The molecular basis of sporadic medullary thyroid carcinoma (MTC) remains elusive. While germline gain-of-function mutations in the RET proto-oncogene cause hereditary MTC, somatic activating RET mutations and loss of heterozygosity of markers in various chromosomal regions representing deletions of tumour suppressor genes, have been described in a variable number of sporadic MTC. A previous report suggested that the presence of a germline variant at RET codon 836 (S836S) was associated with the development of sporadic MTC and, furthermore, that the presence of S836S was highly correlated with somatic RET M918T mutation in the MTC. Thus, we sought to determine if the S836S variant would be associated with sporadic MTC from a completely different population base, that of Andalucia.
DESIGN: This is a case-control study to determine whether the presence of RET germline S836S is correlated with sporadic MTC in Andalucia. PATIENTS: Thirty-two patients with sporadic MTC from the Andalucia region of Spain, serviced by our University Hospital, were ascertained throughout the period 1995-99. Sporadic MTC was defined as a lack of personal or family history suggestive of multiple endocrine neoplasia type 2 (MEN 2) and lack of germline RET mutations which define any MEN 2 subtype. A region and race matched cohort of 250 controls was also obtained. MEASUREMENTS: The frequency of the S836S allele was determined in cases and controls and compared using the standard chi-squared statistic and Fisher's exact test.
RESULTS: The polymorphic allele frequency at codon 836 in the control population (18/500 chromosomes, 3.6%) differed significantly from the MTC case cohort, 9.3% of case chromosomes (six of 64 alleles, Fisher's exact test, two-tailed, P = 0.043).
CONCLUSIONS: Germline RET S836S variant is associated with a two- to three-fold risk of sporadic MTC in the Spanish population, in accordance with a previous study based on German cases. Our observations suggest that this phenomenon might be universal and not limited to Germany.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11589684     DOI: 10.1046/j.1365-2265.2001.01328.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  14 in total

1.  A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma.

Authors:  Salud Borrego; Fred A Wright; Raquel M Fernández; Nita Williams; Manuel López-Alonso; Ramana Davuluri; Guillermo Antiñolo; Charis Eng
Journal:  Am J Hum Genet       Date:  2002-12-09       Impact factor: 11.025

2.  Evaluation of a DHPLC-based assay for rapid detection of RET germline mutations in Italian patients with medullary thyroid carcinoma.

Authors:  I Torrente; F Arturi; L D'Aloiso; A Colosimo; A De Luca; E Ferretti; D Russo; E Chiefari; D Scarpelli; M Bisceglia; B Dallapiccola; S Filetti
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

3.  The frequency of selected polymorphic variants of the RET gene in patients with medullary thyroid carcinoma and in the general population of central Poland.

Authors:  Maria Sromek; Malgorzata Czetwertyńska; Elzbieta Skasko; Joanna Zielińska; Dorota Czapczak; Jan Steffen
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

4.  Significance of the RET proto-oncogene polymorphisms in Turkish sporadic medullary thyroid carcinoma patients.

Authors:  A Gursoy; M F Erdogan; G Erdogan
Journal:  J Endocrinol Invest       Date:  2006-11       Impact factor: 4.256

5.  RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis.

Authors:  Rebecca L Margraf; Rong Mao; W Edward Highsmith; Leonard M Holtegaard; Carl T Wittwer
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

6.  Quantitative assessment of the association between L769L and S836S polymorphisms at RET gene and medullary thyroid carcinoma risk.

Authors:  Yuanqi Zhang; Sanming Wang; Xiaodong Chen; Shengchao Huang; Jianwen Li
Journal:  Tumour Biol       Date:  2014-04-04

7.  2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer.

Authors:  R Elisei; M Alevizaki; B Conte-Devolx; K Frank-Raue; V Leite; G R Williams
Journal:  Eur Thyroid J       Date:  2012-12-19

8.  A complex endocrine conundrum.

Authors:  G Bano; V Siedel; N Beharry; P Wilson; T Cranston; S Hodgson
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

Review 9.  Molecular basis of medullary thyroid carcinoma: the role of RET polymorphisms.

Authors:  Lucieli Ceolin; Débora R Siqueira; Mírian Romitti; Carla V Ferreira; Ana Luiza Maia
Journal:  Int J Mol Sci       Date:  2011-12-27       Impact factor: 5.923

10.  RET polymorphisms and sporadic medullary thyroid carcinoma in a Portuguese population.

Authors:  Patrícia Costa; Rita Domingues; Luís G Sobrinho; Maria João Bugalho
Journal:  Endocrine       Date:  2005-08       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.